Skip to content

Careers
Contact Us
Linkedin
Twitter
Search for:

Home
About
Pipeline
Technology
- COUR Nanoparticle Platform
- Immune Reprogramming
Therapeutic Areas
Partners & Collaborators
Media & Publications
- Press Releases
- Scientific Publications
Videos

Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis

Cour Pharmaceuticals

Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis

Post navigation

Cour Pharma Presents Scientific Poster on Breakthrough Celiac Treatment at 16th Annual International Celiac Disease Symposium

Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease

Leave a Reply

You must be logged in to post a comment.

info@CourPharma.com

Connect

Connect

Pipeline

Pipeline
CNP-101/TAK-101 (Celiac Disease)
CNP-201 (Peanut Allergy)
CNP-104 (Primary Biliary Cholangitis)
CNP-T1D (Type 1 Diabetes)
CNP-MYG (Myasthenia Gravis)
CNP-ITP (Immune Thrombocytopenia Purpura)

Technology

Technology
COUR Nanoparticle Platform
Immune Reprogramming

Videos
Technology
Autoimmune Disease
Food and Environmental Allergies
Gene Therapy

Media & Publications
Press Releases
Scientific Publications
Corporate Deck

Therapeutic Areas

Therapeutic Areas
Autoimmune Diseases: Celiac
Food & Environmental Allergies: Peanut Allergy
Rare Diseases: Primary Biliary Cholangitis
Autoimmune Diseases: Type 1 Diabetes
Rare Diseases: Myasthenia Gravis
Rare Diseases: Immune Thrombocytopenia Purpura
Protein Replacement: Gene Therapy

close ×

About
Partners & Collaborators
Careers
Contact Us
Sitemap

Website by Axxiem

© Copyright . All Right Reserved

Privacy | Terms of Use